04:29 PM EDT, 05/02/2025 (MT Newswires) -- NurExone Biologic ( NRXBF ) after close of trade Friday announced it is deepening its engagement with the European financial and healthcare communities through participation in three upcoming events.

In a statement it said "this increased activity follows NurExone's recent announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN -- underscoring the company's momentum and expansion within the biotechnology sector".

CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a leading investment conference for German-speaking markets including Germany, Austria, and Switzerland.

NurExone plans to maintain an active presence at key European conferences throughout 2025 to "deepen investor relations and foster strategic collaborations" across the healthcare and biotech landscape.

"Our participation in INVEST 2025 reflects NurExone's growing commitment to the European investment community, particularly our expanding German-speaking investor base," said Dr. Shaltiel. "We are building long-term relationships with stakeholders who share our vision for the transformative potential of exosome-based therapeutics."

The company closed trading at $0.69 per share, down 2.82%.